Primary biliary cholangitis (PBC; previously referred to as primary biliary cirrhosis) is characterized by a T-lymphocyte-mediated attack on small intralobular bile ducts.

Primary Biliary Cholangitis (PBC) is considered an autoimmune disease because of its hallmark serologic signature, antimitochondrial antibody (AMA), and specific bile duct pathology. The …

Dec 10, 2020 · Primary biliary cholangitis (PBC) is a chronic, progressive cholestatic liver disease with granulomatous destruction of interlobular bile ducts, leading to fibrosis and ultimately …

Mar 25, 2025 · Primary biliary cholangitis (PBC) is a chronic progressive cholestatic liver disease that is the cause of 1-2% of deaths from cirrhosis and constitutes the third most common …

LOMA is a freely and easily accessible database, currently containing 1302 molecular associations to AIH, CCC, HCC, liver fibrosis, NASH, PBC and PSC. In order to establish this …

Feb 12, 2023 · Primary biliary cholangitis (PBC), formerly termed primary biliary cirrhosis, is an autoimmune disorder that gradually destroys intrahepatic bile ducts, resulting in periportal …

Nov 14, 2023 · There's no cure for primary biliary cholangitis, but medicines are available to help slow the progression of the disease and prevent complications. Options include: …

The AASLD 2018 PBC Guidance provides a data‐supported approach to screening, diagnosis, and clinical management of patients with PBC.

Primary biliary cholangitis (PBC) is a chronic and progressive autoimmune liver disease characterized by the destruction of the small intrahepatic bile ducts and a variable clinical …

AB Currently, the only first-line therapy for primary biliary cholangitis (PBC) approved by the US Food and Drug Administration (FDA) is ursodeoxycholic acid. This treatment is weight-based; …